A MICROSIMULATION MODEL FOR HIGH-RISK STAGE II AND STAGE III COLON CANCER SURVIVORS FOLLOWING THE CURRENT GUIDELINES

被引：0
|
作者：
Samur, S. [1 ]
Gursel, E. [2 ,3 ]
Gu, N. Y.
Palomares, M. [3 ]
Sahinkoc, M. [4 ]
Hoban, O. [2 ]
Cuyun, Carter G. [3 ]
Ayer, T. [5 ]
Chhatwal, J. [4 ]
Parikh, A. [4 ]
Neugut, A., I [6 ]
机构：
[1] Value Analyt Labs, Chantilly, VA USA
[2] Value Analyt Labs, Boston, MA USA
[3] Exact Sci, Madison, WI USA
[4] Harvard Med Sch, Boston, MA USA
[5] Georgia Inst Technol, Atlanta, GA USA
[6] Columbia Univ, New York, NY USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
P59
引用
收藏
页码：S14 / S14
页数：1
相关论文
共 50 条
  • [1] CLINICAL OUTCOMES OF LOW-RISK STAGE II COLON CANCER SURVIVORS ADHERING TO GUIDELINES: A MICROSIMULATION MODEL
    Gursel, E.
    Samur, S.
    Gu, N. Y.
    Palomares, M.
    Sahinkoc, M.
    Erdogan, Z. M.
    Cuyun, Carter G.
    Ayer, T.
    Chhatwal, J.
    Neugut, A., I
    Parikh, A.
    VALUE IN HEALTH, 2024, 27 (06) : S13 - S13
  • [2] The effect of gaps in chemotherapy on survival in patients with high-risk stage II and stage III colon cancer
    Sada, Yvonne
    Duan, Zhigang
    El-Serag, Hashem
    Davila, Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [3] Adherence to NCCN Guidelines is Associated with Improved Survival in High Risk Stage II and Stage III Colon Cancer
    Boland, G. M.
    Chiang, Y.
    Chagpar, R.
    Xing, Y.
    Hu, C.
    Feig, B. W.
    Chang, G. J.
    You, Y.
    Cormier, J. N.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S100 - S100
  • [4] Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration
    Cruz, Jan Paolo M.
    Pales, Chris George C.
    Kim, Kwang Min
    Kim, Young Wan
    JOURNAL OF BUON, 2018, 23 (03): : 568 - 573
  • [5] Study of a High-Risk Group of Stage II Colon Cancer
    Hirosawa, Tomoichiro
    Itabashi, Michio
    Bamba, Yoshiko
    Ogawa, Shinpei
    Sirotani, Noriyasu
    Kameoka, Shingo
    INTERNATIONAL SURGERY, 2009, 94 (02) : 130 - 135
  • [6] IDENTIFICATION OF HIGH-RISK PATIENTS IN STAGE II COLON CANCER
    Lanza, Giovanni
    Gafa, Roberta
    Santini, Alessandra
    Maestri, Iva
    Guerzoni, Laura
    Liboni, Alberto
    Azzena, Gianfranco
    Lelli, Giorgio
    Cavazzini, Luigi
    ANNALS OF ONCOLOGY, 2004, 15 : 66 - 66
  • [7] Biomarker for high-risk patients with stage II colon cancer
    Watanabe, Toshiaki
    LANCET ONCOLOGY, 2013, 14 (13): : 1247 - 1248
  • [8] Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
    Hu, Huabin
    Wu, Zehua
    Wang, Chao
    Huang, Yan
    Zhang, Jianwei
    Cai, Yue
    Xie, Xiaoyu
    Li, Jianxia
    Shen, Cailu
    Li, Weiwei
    Ling, Jiayu
    Xu, Xuehu
    Deng, Yanhong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa
    Tan, Sarah Xinhui
    Pumpalova, Yoanna
    Rogers, Alexandra M. M.
    Bhatt, Kishan
    Herbst, Candice-lee
    Ruff, Paul
    Neugut, Alfred I. I.
    Hur, Chin
    CANCER MEDICINE, 2023, 12 (14): : 15515 - 15529
  • [10] Association of NCCN guideline adherence with improved survival in high-risk stage II and stage III colon cancer.
    Boland, Genevieve Marie
    Chiang, Yj
    Chagpar, Ryaz
    Xing, Yan
    Hu, Chung-Yuan
    Feig, Barry W.
    Chang, George J.
    You, Y. Nancy
    Cormier, Janice N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345